See the DrugPatentWatch profile for viberzi
What is Viberzi and What Are its Uses?
Viberzi (eluxadoline) is a medication prescribed to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1]. It works by acting on receptors in the gut to slow down intestinal motility and reduce abdominal pain [1].
When Does Viberzi's Patent Protection End?
The patent exclusivity for Viberzi is set to expire in the United States in December 2026 [2]. This date marks when generic versions of the drug could potentially become available.
Can Generic Versions of Viberzi Be Approved Before Patent Expiry?
While the primary patent for Viberzi expires in late 2026, the possibility of earlier generic entry depends on various factors, including the resolution of any pending patent litigation. DrugPatentWatch.com tracks these patent landscapes and potential challenges [2].
What Are the Potential Risks and Side Effects of Viberzi?
Viberzi carries a risk of serious side effects, including pancreatitis and sphincter of Oddi dysfunction, particularly in patients who have had their gallbladder removed [1]. Other common side effects include constipation, nausea, abdominal pain, and respiratory tract infection [1]. It is not recommended for patients without a gallbladder or those with severe liver problems [1].
How Does Viberzi Compare to Other IBS-D Treatments?
Viberzi is one of several treatment options for IBS-D. Other medications may include antidiarrheals, antispasmodics, or other targeted therapies, depending on the individual patient's symptoms and medical history [3]. The choice of treatment often involves considering efficacy, side effect profiles, and patient-specific factors.
What Is the Regulatory Status of Viberzi?
Viberzi is approved by the U.S. Food and Drug Administration (FDA) for the specified indication of IBS-D [1]. Generic drug approval follows a separate regulatory pathway, requiring demonstration of bioequivalence to the reference listed drug.
What Are the Next Steps for Generic Viberzi Manufacturers?
Once patent exclusivity ends and regulatory hurdles are cleared, generic manufacturers can begin marketing their versions of eluxadoline. The availability of generic options typically leads to lower drug prices.
Sources
1. https://www.viberzi.com/
2. https://drugpatentwatch.com/
3. Information on alternative treatments for IBS-D is based on general medical knowledge and not attributed to a specific source in the provided information.